Up over 900%: Is it too late to buy this incredible ASX tech stock?

MotleyFool

03/18

4DMedical Ltd (ASX: 4DX) shares are trading 2% higher in afternoon trade on Wednesday. At the time of writing, the shares are trading at $3.87 each. The shares are now down 14.10% year to date. The ...

网页链接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2620828300"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2620828300\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2620828300?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-18 11:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620828300","market":"nz","top_or_hot":-1,"title":"Up over 900%: Is it too late to buy this incredible ASX tech stock?","media":"MotleyFool","content":"<div>\n<p>4DMedical Ltd (ASX: 4DX) shares are trading 2% higher in afternoon trade on Wednesday. At the time of writing, the shares are trading at $3.87 each. The shares are now down 14.10% year to date.\nThe ...</p>\n\n<a href=\"https://www.fool.com.au/2026/03/18/up-over-900-is-it-too-late-to-buy-this-incredible-asx-tech-stock/\">网页链接</a>\n\n</div>\n","source":"motleyfoolau_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Up over 900%: Is it too late to buy this incredible ASX tech stock?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUp over 900%: Is it too late to buy this incredible ASX tech stock?\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">MotleyFool</strong><span class=\"h-time small\">2026-03-18 11:11</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>4DMedical Ltd (ASX: 4DX) shares are trading 2% higher in afternoon trade on Wednesday. At the time of writing, the shares are trading at $3.87 each. The shares are now down 14.10% year to date.\nThe ...</p>\n\n<a href=\"https://www.fool.com.au/2026/03/18/up-over-900-is-it-too-late-to-buy-this-incredible-asx-tech-stock/\">网页链接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://www.fool.com.au/2026/03/18/up-over-900-is-it-too-late-to-buy-this-incredible-asx-tech-stock/\">MotleyFool</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7094","symbol_name":"醫療保健技術","start_time":0,"source_url":"https://www.fool.com.au/2026/03/18/up-over-900-is-it-too-late-to-buy-this-incredible-asx-tech-stock/","article_id":"2620828300","we_media_id":null,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/18/up-over-900-is-it-too-late-to-buy-this-incredible-asx-tech-stock/","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2620828300","pubTimestamp":1773803486,"columns":[],"sourceInfo":{"source_id":"motleyfoolau_stock","name":"MotleyFool"},"weMediaInfo":null,"summary":"4DMedical Ltd  shares are trading 2% higher in afternoon trade on Wednesday. At the time of writing, the shares are trading at $3.87 each. The shares are now down 14.10% year to date.The decline might look concerning on the surface, but it has barely dented the company's gains over the past 12 months. At the time of writing, 4DMedical shares are trading an enormous 950% higher than this time last year.What has happened to the ASX tech stock's shares?4DMedical is a healthcare technology company that develops imaging software for healthcare providers to analyse airflow through the lungs. It helps identify and treat lung andrespiratory diseases ranging from asthma to lung cancer.The company saw its share price explode in 2025 after its flagship product, CT:VQ, received regulatory approvals. It was quickly implemented and adopted through partnerships and commercial contracts with healthcare organisations.This month, 4DMedical was also added to the All Ordinaries Index  and the S&P/ASX 300 ","collect":0,"end_time":0,"defaultTopTitle":"fool.com.au","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7094":"医疗保健技术","XKO.AU":"标普/澳交所 300指数","XAO.AU":"标普/澳交所 普通股指数","4DX.AU":"4DMEDICAL LTD"},"translate_title":"上涨超过900%：现在购买这只令人难以置信的ASX科技股还来得及吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XKO.AU":1,"XAO.AU":1,"4DX.AU":1},"content_text":"4DMedical Ltd (ASX: 4DX) shares are trading 2% higher in afternoon trade on Wednesday. At the time of writing, the shares are trading at $3.87 each. The shares are now down 14.10% year to date.\nThe decline might look concerning on the surface, but it has barely dented the company's gains over the past 12 months. At the time of writing, 4DMedical shares are trading an enormous 950% higher than this time last year.\nImage source: Getty Images\nWhat has happened to the ASX tech stock's shares?\n4DMedical is a healthcare technology company that develops imaging software for healthcare providers to analyse airflow through the lungs. It helps identify and treat lung and respiratory diseases ranging from asthma to lung cancer.\nThe company saw its share price explode in 2025 after its flagship product, CT:VQ, received regulatory approvals. It was quickly implemented and adopted through partnerships and commercial contracts with healthcare organisations.\n4DMedical has already signed contracts with hospitals and medical providers, primarily across the US. Stanford University, the University of Miami, Cleveland Clinic and UC San Diego Health have all rolled out the technology at their centres.\nIn short, 4DMedical moved from a research and development business trialling new technology, to a globally commercial business within a very short period of time.\nThere is no price-sensitive news out of the company to explain the softening share price in 2026. But after such an enormous price tally in 2025, it's likely that investors are taking their gains off the table.\nWhat's next for the company in 2026?\nDevelopment and rapid adoption of the company's technology also mean 4DMedical has smashed its milestone goals. \nIn 2026, 4DMedical will focus on accelerating the rollout of its newly FDA-approved CT:VQ imaging product through more strategic partnerships and new contracts. \nApprovals have been secured in Canada and New Zealand. The company is now actively progressing commercialisation plans in Europe and Australia.\nThis month, 4DMedical was also added to the All Ordinaries Index (ASX: XAO) and the S&P/ASX 300 Index (ASX: XKO).\nIs it too late to buy the ASX tech stock, or is there more upside to come?\nDespite the strong rally over the past year and the 2026 sell-off, most analysts remain very bullish on the stock's outlook.\nTradingView data shows that two out of three analysts have a strong buy rating on the shares, while one has a strong sell stance on the stock.\nThe maximum target price is $4.90, implying another 27% upside for investors at the time of writing.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}